JENS FR. REHFELD, M.D.; FLEMMING STADIL, M.D.; LARS-INGE LARSSON, M.D.; FRANK SUNDLER, M.D.; ROLF HÅKANSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The NIH conference on current concepts of islet cell tumors (1) contains some questionable statements about gastrin, which may justify the following comments.
1. In the summary (page 239) and later (page 243), it is stated that an increase of circulating "big" gastrin may be the most specific finding in the Zollinger-Ellison syndrome. The references cited in that context (their References 55 and 56) do not support such a suggestion. On the contrary, it has been shown that the fraction of "big" gastrin, (preferably called gastrin-33* ) in serum from Zollinger-Ellison patients is of the same order
REHFELD JF, STADIL F, LARSSON L, et al. Gastrin and Islet-Cell Tumors. Ann Intern Med. 1974;80:778. doi: https://doi.org/10.7326/0003-4819-80-6-778
Download citation file:
Published: Ann Intern Med. 1974;80(6):778.
Gastroenterology/Hepatology, Hematology/Oncology, Pancreatic Disease.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use